The Pathophysiological Role and Therapeutic Potential of C-Type Natriuretic Peptide in Pulmonary Hypertension
Year: 2023
Type: article
Abstract: Background: Pulmonary hypertension (PH) is a multi-faceted disease characterised by vascular remodelling and elevated pressure in the pulmonary arteries. Whilst targeted pharmacological and surgical treatments significantly improve outcomes in some PH subgroups, many patients still develop fatal right heart failure, even with optimal therapy. In the systemic circulation, C-type natriuretic peptide (CNP) acts on two biological receptors, natriuretic peptide receptor (NPR)-B, and NPR-C, to modulate vascular tone, angiogenesis, inflammation, smooth muscle and endothelial cell proliferation, cardiomyocyte hypertrophy and fibrosis. In addition, NPR-C also functions as a clearance receptor. A (patho)physiological function for this signalling pathway in the cardiopulmonary circulation has not been established. Exploiting cell-specific transgenic mouse strains, the role of CNP in the development of experimental PH and right ventricular hypertrophy (RVH) was explored. Methods: Wildtype (WT), global CNP knockout (gbCNP-/-), endothelial CNP knockout (ecCNP-/-), cardiomyocyte CNP knockout (cmCNP-/-) and global natriuretic peptide receptor (NPR)-C null animals (NPR-C-/-) were exposed to normoxia (21% O2; 5 weeks; ‘controls’) or hypoxia (10% O2; 5 weeks) plus the vascular endothelial growth factor (VEGF) receptor antagonist Sugen (3x20mg/kg; subcutaneous; days 0, 7 & 14). PH was quantified by determination of right ventricular systolic pressure (RVSP) and heart chamber weights were measured to evaluate RVH (right ventricle to left ventricle plus septum ratio; RV/[LV+S]). Pulmonary vascular remodelling and RV fibrosis were assessed by α-smooth muscle actin staining and picrosirius red staining, respectively. To investigate the therapeutic potential of CNP, and to examine the effects of receptor specific CNP signalling, the peptide was administered to WT and NPR-C-/- mice with established PH via subcutaneous minipump. Results: Male gbCNP / mice exposed to exposed to Sugen plus hypoxia (SuHx) exhibited increased RVSP versus WT SuHx animals. This phenotype was recapitulated in male ecCNP-/- mice, with the addition of accentuated pulmonary vascular remodelling and elevated RVH. Cardiopulmonary pressure and pulmonary vascular remodelling were unaltered in male NPR-C-/- animals, suggesting the protective effects of endogenous CNP are primarily mediated by NPR-B in the pulmonary vasculature. Whilst loss of cardiomyocyte derived CNP was compensated by other cell types in the heart, global NPR-C deficiency exacerbated the development of RVH and fibrosis in male mice, highlighting a key cardioprotective role for NPR-C in the right heart. These effects were highly sex-dependent; deletion of CNP or NPR-C from female SuHx mice did not exacerbate the development of PH or RV remodelling. CNP infusion reduced RVSP in male WT SuHx mice by promoting anti-proliferative, anti-remodelling bone morphogenetic protein (BMP) signalling in the lungs. Reversal of PH was also achieved in NPR-C-/- animals, further highlighting the critical vasoprotective action of NPR-B in the pulmonary circulation. Conclusions: In sum, these data elucidate the protective role of endogenous CNP signalling against the development of PH and suggest that targeting NPR-B and NPR-C, respectively, may be of therapeutic benefit in the context of pulmonary vascular disease and right heart remodelling.
Author: Dignam, J
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7051468398
